000 04367nam a22005055i 4500
999 _c200458683
_d76895
003 TR-AnTOB
005 20231109085931.0
007 cr nn 008mamaa
008 221027s2022 sz | s |||| 0|eng d
020 _a9783031093883
024 7 _a10.1007/978-3-031-09388-3
_2doi
040 _aTR-AnTOB
_beng
_erda
_cTR-AnTOB
041 _aeng
060 _aWR 165
072 7 _aMJK
_2bicssc
072 7 _aMED017000
_2bisacsh
072 7 _aMJK
_2thema
096 _aWR165EBK
245 1 0 _aDrug Eruptions
_h[electronic resource] /
_cedited by Haur Yueh Lee, Daniel Creamer.
250 _a1st ed. 2022.
264 1 _aCham :
_bSpringer International Publishing :
_bImprint: Springer,
_c2022.
300 _a1 online resource
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
490 1 _aUpdates in Clinical Dermatology,
_x2523-8892
505 0 _aSection I: General Considerations -- Chapter 1: Pharmacogenetics of Cutaneous Adverse Drug Reactions -- Chapter 2: Mechanisms of Drug Hypersensitivity -- Chapter 3: Histopathology of Cutaneous Adverse Drug Reactions -- Chapter 4: Skin Tests in Evaluating Drug Eruptions -- Chapter 5: In vitro Drug Allergy Testing -- Section II: Reaction Patterns -- Chapter 6: Drug-induced urticaria -- Chapter 7: Exanthematous Drug Eruptions -- Chapter 8: Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis -- Chapter 9: Acute Generalized Exanthematous Pustulosis -- Chapter 10: Drug Reaction Eosinophilia and Systemic Symptoms (DRESS) -- Chapter 11: Fixed Drug Eruptions and Generalized Bullous Fixed Drug Eruptions -- Chapter 12: Lichenoid Drug Eruptions -- Chapter 13: Drug-induced Connective Tissue Disorders -- Chapter 14: Drug-induced Vasculitis -- Chapter 15: Drug-induced Autoimmune Bullous Diseases -- Chapter 16: Other Drug-induced Inflammatory Skin Reactions -- Chapter 14: Drug-induced Vasculitis -- Chapter 15: Drug-induced Autoimmune Bullous Diseases -- Chapter 16: Other Drug-induced Inflammatory Skin Reactions -- Chapter 17: Drug-induced Photosensitivity -- Chapter 18: Drug-induced Pruritus Without Primary Rash -- Chapter 19: Drug-induced Nail Changes -- Chapter 20: Drug-induced Hair Changes -- Chapter 21: Drug-induced Pigmentary Disorders -- Section III: Special Drug Categories -- Chapter 22: Immediate and Delayed Reactions to Beta-lactams -- Chapter 23: Hypersensitivity Reactions to Iodinated Radiocontrast Media -- Chapter 24: Cutaneous Adverse Reactions to Biologic Agents -- Chapter 25: Cutaneous Reactions to Oncologic Targeted Therapy -- Chapter 26 :Cutaneous Reactions to Oncologic Immunotherapy. .
520 _aCutaneous adverse drug reactions are common and range from the benign to those which are life-threatening. The clinical presentation of these dermatoses is varied and many may mimic common skin conditions. Consequently, diagnosis in drug-induced skin disease is challenging and the treatment considerations are complex. This book aims to bridge the divide between dermatology and allergy by providing a comprehensive review on the pathomechanisms and clinical features of cutaneous adverse drug reactions. Broken up into three distinct sections: General Considerations, Reaction Patterns, and Special Drug Categories, these chapters cover the common and rare adverse skin reactions and provide information on recent advances - particularly immunopathology and pharmacogenetics - as well as highlighting new adverse drug signals and novel therapies. Drug Eruptions is a must-have resource for dermatologists, allergists, internal physicians and general practitioners.
650 0 _aDermatology.
650 0 _aAllergy.
650 1 4 _aDermatology.
650 2 4 _aAllergology.
653 0 _aDrug Eruptions
700 1 _aLee, Haur Yueh.
_eeditor.
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
700 1 _aCreamer, Daniel.
_eeditor.
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
710 2 _aSpringerLink (Online service)
830 0 _aUpdates in Clinical Dermatology,
_x2523-8892
856 4 0 _uhttps://doi.org/10.1007/978-3-031-09388-3
_3Springer eBooks
_zOnline access link to the resource
942 _2NLM
_cEBK